文献速递肿瘤 PET/CT

68Ga标记成纤维细胞激活蛋白抑制剂(68Ga-FAPI)PET用于胰腺腺癌:来自68Ga-FAPI PET观察性试验的数据

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.
PubMed 文献 · J Nucl Med · 2023-12-01

在疑似或确诊胰腺癌患者中开展的68Ga-FAPI PET观察性试验纳入62例(97%)进行分析,所有患者接受增强CT,38例另接受18F-FDG PET。68Ga-FAPI SUVmax与组织病理FAP表达显著相关(Spearman r=0.48,P=0.04),且检出率和诊断准确性高于18F-FDG PET/CT。

要点

  • 68Ga-FAPI PET的SUVmax与组织病理FAP表达显著相关(Spearman r=0.48,P=0.04)。
  • 组织病理验证病灶中,68Ga-FAPI PET按患者和按区域灵敏度均为100%,PPV分别为96.3%和97.0%。
  • 头对头比较中68Ga-FAPI检出肿瘤多于18F-FDG或增强CT(按病灶84.7% vs 46.5% vs 52.9%)。

核心结论

  • 研究证实胰腺癌患者68Ga-FAPI PET SUVmax与组织病理FAP表达相关。
  • 68Ga-FAPI PET检出率和诊断准确性高,优于18F-FDG PET/CT。
  • 68Ga-FAPI可能成为胰腺癌检查的有力诊断工具。

研究设计与样本

  • 68Ga-FAPI PET观察性试验(NCT04571086)纳入64例疑似或确诊胰腺癌患者中的62例(97%)进行分析。
  • 所有患者接受增强CT,38例患者另接受18F-FDG PET。
  • 数据集由2名设盲读者判读。

主要发现

  • 主要终点达成:68Ga-FAPI SUVmax与组织病理FAP表达显著相关(Spearman r=0.48,P=0.04)。
  • 组织病理验证病灶中,68Ga-FAPI PET按患者灵敏度100%、PPV 96.3%,按区域灵敏度100%、PPV 97.0%。
  • 头对头比较中,68Ga-FAPI按病灶检出84.7%,18F-FDG为46.5%,增强CT为52.9%。
  • 按患者检出:68Ga-FAPI 97.4%,18F-FDG 73.7%,增强CT 92.1%。
  • 按区域检出:68Ga-FAPI 32.6%,18F-FDG 18.8%,增强CT 23.7%。

临床怎么用

  • 原文结论指出68Ga-FAPI可能成为胰腺癌检查的有力诊断工具,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus is a promising target for imaging and therapy. Preliminary data on PET imaging with radiolabeled FAP inhibitors (FAPIs) demonstrate superior tumor detection. Here we assess the accuracy of FAP-directed PET in patients with pancreatic cancer. Methods: Of 64 patients with suspected or proven pancreatic cancer, 62 (97%) were included in the data analysis of the 68Ga-FAPI PET observational trial (NCT04571086). All of these patients underwent contrast-enhanced CT, and 38 patients additionally underwent 18F-FDG PET. The primary study endpoint was the association of 68Ga-FAPI PET uptake intensity and histopathologic FAP expression. Secondary endpoints were detection rate, diagnostic performance, interreader reproducibility, and change in management. Datasets were interpreted by 2 masked readers. Results: The primary endpoint was met: The association between 68Ga-FAPI SUVmax and histopathologic FAP expression was significant (Spearman r, 0.48; P = 0.04). For histopathology-validated lesions, 68Ga-FAPI PET showed high sensitivity and positive predictive values (PPVs) on per-patient (sensitivity, 100%; PPV, 96.3%) and per-region (sensitivity, 100%; PPV, 97.0%) bases. In a head-to-head comparison versus 18F-FDG or contrast-enhanced CT, 68Ga-FAPI detected more tumor on a per-lesion (84.7% vs. 46.5% vs. 52.9%), per-patient (97.4% vs. 73.7% vs. 92.1%), or per-region (32.6% vs. 18.8% vs. 23.7%) basis, respectively. 68Ga-FAPI PET readers showed substantial overall agreement on the basis of the Fleiss κ: primary κ, 0.77 (range, 0.66-0.88). Minor and major changes in clinical management occurred in 5 patients (8.4%) after 68Ga-FAPI PET. Conclusion: We confirmed an association of 68Ga-FAPI PET SUVmax and histopathologic FAP expression in pancreatic cancer patients. Additionally, we found high detection rate and diagnostic accuracy, superior to those of 18F-FDG PET/CT. 68Ga-FAPI might become a powerful diagnostic tool for pancreatic cancer work-up.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kessler L, Hirmas N, Pabst KM, et al. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. J Nucl Med. 2023. PMID: 37973185. doi:10.2967/jnumed.122.264827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。